BRAF and Miyoshi myopathy: In the CheckMate 067 clinical trial, patients with untreated and unresectable MM who received a combination therapy with nivolumab and ipilimumab displayed a 6.5-year OS of 57% in those with BRAF-mutant and 46% in those with BRAF-wild-type tumors [7].